- Home
- AVTX vs QNCX Comparison
AVTX vs QNCX Comparison
Compare AVTX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- QNCX
- Stock Information
- Founded
- AVTX 2011
- QNCX 2012
- Country
- AVTX United States
- QNCX United States
- Employees
- AVTX N/A
- QNCX N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVTX Health Care
- QNCX Health Care
- Exchange
- AVTX Nasdaq
- QNCX Nasdaq
- Market Cap
- AVTX 57.4M
- QNCX 47.7M
- IPO Year
- AVTX 2015
- QNCX 2019
- Fundamental
- Price
- AVTX $4.94
- QNCX $1.60
- Analyst Decision
- AVTX Strong Buy
- QNCX Strong Buy
- Analyst Count
- AVTX 7
- QNCX 5
- Target Price
- AVTX $31.00
- QNCX $8.00
- AVG Volume (30 Days)
- AVTX 99.4K
- QNCX 344.4K
- Earning Date
- AVTX 08-11-2025
- QNCX 08-12-2025
- Dividend Yield
- AVTX N/A
- QNCX N/A
- EPS Growth
- AVTX N/A
- QNCX N/A
- EPS
- AVTX N/A
- QNCX N/A
- Revenue
- AVTX $441,000.00
- QNCX N/A
- Revenue This Year
- AVTX N/A
- QNCX N/A
- Revenue Next Year
- AVTX N/A
- QNCX N/A
- P/E Ratio
- AVTX N/A
- QNCX N/A
- Revenue Growth
- AVTX N/A
- QNCX N/A
- 52 Week Low
- AVTX $3.39
- QNCX $0.51
- 52 Week High
- AVTX $16.00
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- AVTX 57.06
- QNCX 64.56
- Support Level
- AVTX $4.50
- QNCX $1.43
- Resistance Level
- AVTX $5.05
- QNCX $1.68
- Average True Range (ATR)
- AVTX 0.32
- QNCX 0.14
- MACD
- AVTX 0.03
- QNCX 0.02
- Stochastic Oscillator
- AVTX 81.36
- QNCX 84.91
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.